A management shakeup at one of Seattle’s largest research institutions has some observers scratching their heads. Seattle Biomedical Research Institute officials say they’re “restructuring” in order to deliver their drug discoveries more quickly to the developing world. But some familiar with SBRI say they don’t understand how the departure of two top executives who managed the organization during a period of dramatic growth could help achieve that goal.
